KR930702527A - gp160의 유도체 및 보조약을 함유하는 gp160 또는 그의 유도체를 기재로하는 백신 - Google Patents

gp160의 유도체 및 보조약을 함유하는 gp160 또는 그의 유도체를 기재로하는 백신

Info

Publication number
KR930702527A
KR930702527A KR1019930700978A KR930700978A KR930702527A KR 930702527 A KR930702527 A KR 930702527A KR 1019930700978 A KR1019930700978 A KR 1019930700978A KR 930700978 A KR930700978 A KR 930700978A KR 930702527 A KR930702527 A KR 930702527A
Authority
KR
South Korea
Prior art keywords
derivatives
adjuvants
vaccine based
containing derivatives
vaccine
Prior art date
Application number
KR1019930700978A
Other languages
English (en)
Other versions
KR100194079B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909021175A external-priority patent/GB9021175D0/en
Priority claimed from GB919106048A external-priority patent/GB9106048D0/en
Application filed filed Critical
Publication of KR930702527A publication Critical patent/KR930702527A/ko
Application granted granted Critical
Publication of KR100194079B1 publication Critical patent/KR100194079B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019930700978A 1990-09-28 1991-09-21 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법 KR100194079B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9021175.6 1990-09-28
GB909021175A GB9021175D0 (en) 1990-09-28 1990-09-28 Novel compounds
GB919106048A GB9106048D0 (en) 1991-03-21 1991-03-21 Vaccines
GB9106048.3 1991-03-21
PCT/EP1991/001810 WO1992006113A2 (en) 1990-09-28 1991-09-21 DERIVATIVES OF gp160 AND VACCINES BASED ON gp160 OR A DERIVATIVE THEREOF, CONTAINING AN ADJUVANT

Publications (2)

Publication Number Publication Date
KR930702527A true KR930702527A (ko) 1993-09-09
KR100194079B1 KR100194079B1 (ko) 1999-06-15

Family

ID=26297726

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930700978A KR100194079B1 (ko) 1990-09-28 1991-09-21 Hiv 감염 예방 또는 치료용 제약학적 조성물 및 이의 제조방법

Country Status (10)

Country Link
EP (2) EP0644201A1 (ko)
JP (1) JPH06501151A (ko)
KR (1) KR100194079B1 (ko)
AU (1) AU654970B2 (ko)
CA (1) CA2092827A1 (ko)
IE (1) IE913385A1 (ko)
MX (1) MX9101275A (ko)
NZ (1) NZ239948A (ko)
PT (1) PT99063B (ko)
WO (1) WO1992006113A2 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US6171596B1 (en) 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
ES2250151T3 (es) * 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein

Also Published As

Publication number Publication date
PT99063A (pt) 1992-08-31
IE913385A1 (en) 1992-04-08
EP0644201A1 (en) 1995-03-22
KR100194079B1 (ko) 1999-06-15
MX9101275A (es) 1992-05-04
AU8510991A (en) 1992-04-28
WO1992006113A2 (en) 1992-04-16
CA2092827A1 (en) 1992-03-29
AU654970B2 (en) 1994-12-01
NZ239948A (en) 1993-07-27
WO1992006113A3 (en) 1992-08-20
JPH06501151A (ja) 1994-02-10
EP0550485A1 (en) 1993-07-14
PT99063B (pt) 1999-07-30

Similar Documents

Publication Publication Date Title
DK0671948T3 (da) Vaccinepræparat indeholdende adjuvanser
KR900011476A (ko) 백신 제제
DE69126606D1 (de) Vakzine
ATA901392A (de) Hepatitis-c-diagnosemittel und -impfstoffe
NO921012D0 (no) Farmasoeytiske preparater og deres anvendelse
DK272889A (da) Vaccine
BR9107294A (pt) Derivados do GP160 e vacinas baseadas no GP160 ou um derivado do mesmo, contendo um adjuvante
EE9400183A (et) Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine
DK0480052T3 (da) Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet
DK189788D0 (da) Vaccine
DE68923860D1 (de) Derivate von Alkoholen und Ethern.
NO914233D0 (no) Fremgangsmaate for fremstilling av muramyldipeptidderivater og influensavaksine som omfatter derivatene
KR930702527A (ko) gp160의 유도체 및 보조약을 함유하는 gp160 또는 그의 유도체를 기재로하는 백신
TR24895A (tr) PIRIMIDIN TüREVLERI,BUNLARIN ISTIHSAL EDILMESI VE KULLANILMASI
NO940027L (no) Fremgangsmaate for fremstilling av derivater av B-fenylisorerin og derivatenes anvendelse
NO882462D0 (no) Fremstilling og bruk av fenolderivater.
DK95489D0 (da) Anvendelse af quinolizin- og quinolizinonderivater til fremstilling af et laegemiddel
DE69032787D1 (de) Mutantes pseudorabiesvirus und dasselbe enthaltende vakzine
NO921086L (no) Fremgangsmaate for fremstilling og anvendelse av substituerte 2',3'-didesoksy-5-trifluormetyluridiner
DK449188D0 (da) 2'-deoxy-5-fluoruridinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
DK289090D0 (da) Farmaceutisk praeparat samt konjugat af et baktericid og et antistof rettet mod plaquedannende eller caries-inducerende bakterier
DK36387D0 (da) Desinficerende og steriliserende praeparat
NO920009D0 (no) Fremstilling og anvendelse av tienoimidazolderivater
NO912279D0 (no) Fremgangsmaate for fremstilling og anvendelse av eksplosjonssikre 1-dimetylamino-3-dimetylimino-2-arylprop-1-en-salter.
DK75691D0 (da) Ny farmaceutisk anvendelse af fusidin og derivater deraf

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee